Edgar Filing: HORIZON PHARMA, INC.

Date: February 9, 2012

Horizon Pharma, Inc.

/s/ Robert J. De Vaere

Robert J. De Vaere

Executive Vice President and Chief Financial Officer

FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 7, 2012

Horizon Pharma, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-35238	27-2179987
(State of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

520 Lake Cook Road, Suite 520, Deerfield, Illinois		60015
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (224) 383-3000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.05

Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.

On February 7, 2012, the Company amended its Code of Business Conduct and Ethics (the “Code”). The amendments are primarily intended to address in greater detail various aspects of the Company’s business related to the marketing and sale of pharmaceutical products. In particular, the amended Code addresses compliance with applicable laws, regulations and guidelines with respect to (i) interactions with and payments to healthcare professionals, (ii) claims submitted to government healthcare programs, (iii) the handling of patient information, (iv) adverse event reporting, (v) conducting business abroad and (vi) the testing, manufacture, promotion and labeling of pharmaceutical products. The amendments to the Code also incorporate certain aspects of the Company’s employee handbook and the Company’s recently-established compliance program and other internal resources designed to enhance compliance with the Code and applicable laws. The amended Code is available on the Company’s website at www.horizonpharma.com.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.